The fourth and final white paper in our series reviews several concepts of enzyme assays for lysosomal storage disorders (LSDs). Thus far, the series has examined:
1. Key similarities in all the synthetic substrates being used,
2. Key differences between enzymatic assays vs. metabolic assays, and
3. How to optimize workflow when screening X-ALD coupled with LSDs.
To wrap up the series, Baebies examines all the factors that determine enzyme activity and highlights how enzyme assays can be performed with shorter incubation times without incurring additional cost or compromising assay performance. This is especially significant in the case of newborn screening of Pompe disease, where timely intervention results in better outcomes for the patients.